Literature DB >> 31735692

Gender affirming medical care of transgender youth.

Caroline Salas-Humara1, Gina M Sequeira2, Wilma Rossi3, Cherie Priya Dhar4.   

Abstract

The number of gender diverse and transgender youth presenting for treatment are increasing. This is a vulnerable population with unique medical needs; it is essential that all pediatricians attain an adequate level of knowledge and comfort caring for these youth so that their health outcomes may be improved. There are several organizations which provide clinical practice guidelines for the treatment of transgender youth including the WPATH and the Endocrine Society and they recommend that certain eligibility criteria should be met prior to initiation of gender affirming hormones. Medical intervention for transgender youth can be broken down into stages based on pubertal development: pre-pubertal, pubertal and post-pubertal. Pre-pubertally no medical intervention is recommended. Once puberty has commenced, youth are eligible for puberty blockers; and post-pubertally, youth are eligible for feminizing and masculinizing hormone regimens. Treatment with gonadotropin releasing hormone agonists are used to block puberty. Their function is many-fold: to pause puberty so that the youth may explore their gender identity, to delay the development of (irreversible) secondary sex characteristics, and to obviate the need for future gender affirmation surgeries. Masculinizing hormone regimens consists of testosterone and feminizing hormone regimens consist of both estradiol as well as spironolactone. In short term studies gender affirming hormone treatment with both estradiol and testosterone has been found to be safe and improve mental health and quality of life outcomes; additional long term studies are needed to further elucidate the implications of gender affirming hormones on physical and mental health in transgender patients. There are a variety of surgeries that transgender individuals may desire in order to affirm their gender identity; it is important for providers to understand that desire for medical interventions is variable among persons and that a discussion about individual desires for surgical options is recommended.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 31735692     DOI: 10.1016/j.cppeds.2019.100683

Source DB:  PubMed          Journal:  Curr Probl Pediatr Adolesc Health Care        ISSN: 1538-3199


  4 in total

1.  "These Laws Will Be Devastating": Provider Perspectives on Legislation Banning Gender-Affirming Care for Transgender Adolescents.

Authors:  Landon D Hughes; Kacie M Kidd; Kristi E Gamarel; Don Operario; Nadia Dowshen
Journal:  J Adolesc Health       Date:  2021-10-07       Impact factor: 7.830

Review 2.  Embryologic and hormonal contributors to prostate cancer in transgender women.

Authors:  Simita Gaglani; Rajveer S Purohit; Ashutosh K Tewari; Natasha Kyprianou; Dara J Lundon
Journal:  Am J Clin Exp Urol       Date:  2022-04-15

3.  "This Could Mean Death for My Child": Parent Perspectives on Laws Banning Gender-Affirming Care for Transgender Adolescents.

Authors:  Kacie M Kidd; Gina M Sequeira; Taylor Paglisotti; Sabra L Katz-Wise; Traci M Kazmerski; Amy Hillier; Elizabeth Miller; Nadia Dowshen
Journal:  J Adolesc Health       Date:  2020-10-13       Impact factor: 7.830

4.  Navigating Human Immunodeficiency Virus and Primary Care Concerns Specific to the Transgender and Gender-Nonbinary Population.

Authors:  Mark Lieber; Matthew M Hamill; Paul Pham; Elyse Pine; Jill Crank; Maunank Shah
Journal:  Open Forum Infect Dis       Date:  2022-03-23       Impact factor: 3.835

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.